{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:26:01Z","timestamp":1793751961454,"version":"4.6.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,4]]},"DOI":"10.1093\/ehjcvp\/pvag067","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:24:55Z","timestamp":1787570695000},"page":"568-571","source":"Crossref","is-referenced-by-count":0,"title":["Comparative biomarker efficacy of cholesteryl ester transfer protein inhibitors: a network meta-analysis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"first","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL) , Rzgowska 281\/289, Lodz 90-212 ,","place":["Poland"]},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital , Derby Street, Liverpool L7 8TX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1660","authenticated-orcid":false,"given":"Vikash","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Endeavor Center for Cardiovascular Intervention Outcomes Research and Evaluation (ECCORE), Section of Interventional Cardiology, Endeavor Health Cardiovascular Institute , Glenview, IL 60026 ,","place":["USA"]},{"name":"University of Chicago Pritzker School of Medicine , IL 60026 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-9880","authenticated-orcid":false,"given":"Song Peng","family":"Ang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Sarver Heart Center, University of Arizona , Tucson, AZ 85724 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Ahuja","sequence":"additional","affiliation":[{"name":"University of Chicago Pritzker School of Medicine , IL 60026 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saad","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rawalpindi Medical University , Rawalpindi 46000 ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Qamar","sequence":"additional","affiliation":[{"name":"University of Chicago Pritzker School of Medicine , IL 60026 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6666-3999","authenticated-orcid":false,"given":"Agata","family":"Bielecka-D\u0105browa","sequence":"additional","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL) , Rzgowska 281\/289, Lodz 90-212 ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-3735","authenticated-orcid":false,"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Health System\/Albert Einstein College of Medicine , Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth S","family":"Martin","sequence":"additional","affiliation":[{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine , Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-8846","authenticated-orcid":false,"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart , 00168 Rome ,","place":["Italy"]},{"name":"Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola , 00186 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026110318514027900_pvag067-B1","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026110318514027900_pvag067-B2","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/AphA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026110318514027900_pvag067-B3","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B5","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"2026110318514027900_pvag067-B7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B8","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1253\/circj.CJ-16-1324","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor evacetrapib in combination with atorvastatin in Japanese patients with primary hypercholesterolemia","volume":"82","author":"Teramoto","year":"2017","journal-title":"Circ J"},{"key":"2026110318514027900_pvag067-B10","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HPS3\/TIMI55\u2013REVEAL Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B11","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1074248414529621","article-title":"Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study","volume":"19","author":"Gotto","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026110318514027900_pvag067-B13","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"2026110318514027900_pvag067-B14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.amjcard.2017.03.255","article-title":"A multiregional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol","volume":"120","author":"Ballantyne","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026110318514027900_pvag067-B15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2017.03.009","article-title":"Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia","volume":"261","author":"Teramoto","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026110318514027900_pvag067-B16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.atherosclerosis.2016.03.017","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia","volume":"249","author":"Arai","year":"2016","journal-title":"Atherosclerosis"},{"key":"2026110318514027900_pvag067-B17","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"2026110318514027900_pvag067-B18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","article-title":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Sarraju","year":"2025","journal-title":"Lancet"},{"key":"2026110318514027900_pvag067-B19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"2026110318514027900_pvag067-B20","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41591-025-04179-4","article-title":"Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial","volume":"32","author":"Nicholls","year":"2026","journal-title":"Nat Med"},{"key":"2026110318514027900_pvag067-B21","first-page":"1602","article-title":"2023: the year in cardiovascular disease\u2014the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?","volume":"19","author":"Banach","year":"2023","journal-title":"Arch Med Sci"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag067\/70808668\/pvag067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/7\/568\/70808668\/pvag067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/7\/568\/70808668\/pvag067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:51:52Z","timestamp":1793749912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/7\/568\/8771339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,8,28]]},"published-print":{"date-parts":[[2026,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag067","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,28]]}}}